| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919504 | Radiotherapy and Oncology | 2013 | 7 Pages |
Abstract
Prostate cancer patients experience a small worsening of QoL as compared with baseline and as compared with a normal reference population. As co-morbidity modulates patients' post-treatment QoL, a proper assessment of co-morbidity should be included in future longitudinal analyses on QoL.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Wouter Schaake, Martijn de Groot, Wim P. Krijnen, Johannes A. Langendijk, Alfons C.M. van den Bergh,